Author: Ravi Shankar

Oma Savings Bank Plc, stock exchange release, 25 September 2026 at 4.30 p.m. (EEST), other information disclosed to the rules of the exchange

Oma Savings Bank Plc issues a covered bond of EUR 200 million as part of a bond program

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR SUCH OTHER COUNTRIES OR OTHERWISE IN SUCH CIRCUMSTANCES IN WHICH THE OFFERING OF THE NEW NOTES, THE TENDER OFFER OR THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oma Savings Bank Plc (“OmaSp” or the “Company”) issues a covered bond of EUR 200 million. The maturity date of the bond is 2 October 2029, and the loan has a floating interest rate. The ISIN code of the bond is FI4000615059.

The loan issuance will take place under OmaSp’s EUR 4 billion bond program. On 1 September 2026, the Finnish Financial Supervisory Authority approved the base prospectus in respect of OmaSp’s bond program, and the supplement thereto on 21 September 2026.

The base prospectus, the supplement and the final terms of the bond are available in English on the Company’s website at https://www.omasp.fi/investors.

OmaSp has submitted an application for the bond to be admitted to trading on the regulated market maintained by Nasdaq Helsinki Ltd.

Oma Savings Bank Plc

Additional information:
Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi
Sarianna Liiri, CFO, tel. +358 40 835 6712, sarianna.liiri@omasp.fi
Pirjetta Soikkeli, CCO, tel. +358 40 750 0093, pirjetta.soikkeli@omasp.fi

DISTRIBUTION:
Nasdaq Helsinki Ltd
Major media
www.omasp.fi

OmaSp is a solvent and profitable Finnish bank. About 600 professionals provide nationwide services through OmaSp’s 48 branch offices and digital service channels to over 200,000 private and corporate customers. OmaSp focuses primarily on retail banking operations and provides its clients with a broad range of banking services both through its own balance sheet as well as by acting as an intermediary for its partners’ products. The intermediated products include credit, investment and loan insurance products. OmaSp is also engaged in mortgage banking operations.

OmaSp core idea is to provide personal service and to be local and close to its customers, both in digital and traditional channels. OmaSp strives to offer premium level customer experience through personal service and easy accessibility. In addition, the development of the operations and services is customer oriented. The personnel is committed and OmaSp seeks to support their career development with versatile tasks and continuous development. A substantial part of the personnel also own shares in OmaSp.

AS LHV Group announces that during the period 18 to 24 September 2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:

Date	Aggregated volume (pcs)	Weighted average price per day (EUR)
18.09.2026	19,800	3.31
21.09.2026	20,100	3.31
22.09.2026	26,800	3.30375
23.09.2026	20,400	3.295
24.09.2026	26,800	3.2925

LHV Group is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 26 March 2025, and under the conditions decided by the Supervisory Board. The authorized agent for the transactions is AS LHV Pank. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on LHV Group’s investor website.

LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s main subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs nearly 1,200 people. LHV’s banking services are used by more than 514,000 customers, LHV-managed II pillar pension funds have 105,000 active customers and LHV Kindlustus provides insurance protection to 244,000 customers. LHV Bank, a subsidiary of LHV Group, holds a UK banking licence and offers banking services to international financial technology companies, loans to small and medium-sized enterprises and retail banking services.

Investor Relations
Sten Hans Jakobsoo
Head of Investor Relations and Corporate Development
Email: stenhans.jakobsoo@lhv.ee

Communications
Paul Pihlak
Head of Communications
Email: paul.pihlak@lhv.ee 

SANTIAGO, Chile, Sept. 25, 2026 (GLOBE NEWSWIRE) — You are cordially invited to participate in Banco Santander Chile’s (NYSE: BSAC) conference call-webcast on Wednesday November 4, 2026, at 11.00 AM Chile time (9.00 AM ET) where we will discuss 3Q 2026 financial results. The Bank’s Officers participating in the conference call are: Patricia Pérez, CFO, Cristian Vicuña, Chief Strategy Officer & Head of IR and Andres Sansone, Chief Economist. A question and answer session will follow the presentation.

The Management Commentary report will be published on October 30, 2026, before the market opens. The quiet period begins on October 16.

To participate, the webcast presentation can be viewed at: https://mm.closir.com/slides?id=720987

Or please dial in using any of the below numbers:
United Kingdom +44 203 984 9844
USA +1 718 866 4614
Austria +43 720 022981
Brazil +556120171549
Canada +1 587 855 1318
Chile +56228401484
Czech Republic +420 910 880101
Estonia +372 609 4102
Finland +35 8753 26 4477
France +33 1758 50 878
Germany +49 30 25 555 323
Hong Kong +852 3001 6551
Mexico +52 55 1168 9973
Peru +51 1 7060950
Poland +48 22 124 49 59
Russia +7 495 283 98 58
Singapore +65 3138 6816
South Africa +27872500455
South Korea +82 70 4732 5006
Sweden +46 10 551 30 20
Turkey +90 850 390 7512
Ukraine +380 89 324 0624

Participant Passcode: 720987
Please dial in approximately 10 minutes prior to the starting time of the conference.

If you have any questions, please contact Cristian Vicuña at Banco Santander Chile at Cristian.vicuna@santander.cl, Rowena Lambert at Rowena.lambert@santander.cl or Claudia Villalon at claudia.villalon@santander.cl

CONTACT INFORMATION

Cristian Vicuña
Investor Relations
Banco Santander Chile
Bandera 140, Floor 20
Santiago, Chile
Email: irelations@santander.cl
Website: www.santander.cl

About Santander

Banco Santander Chile is one of the companies with the highest risk ratings in Latin America, with an A2 rating from Moody’s, A- from Standard & Poor’s, A+ from the Japan Credit Rating Agency, and AA- from HR Ratings. All ratings have a stable outlook as of the date of this report.

As of June 30, 2026, the Bank has total assets of CLP 70,323,331 million (US$ 76,348million), total gross loans (including loans owed by banks) at amortized cost of CLP 41,426,628 million (US$ 44,976 million), total deposits of CLP 32,390,791 million (US$ 35,166 million), and shareholders’ equity of CLP 4,974,214 million (US$ 5,400 million). The BIS capital ratio is 16.6%, with a core capital ratio of 11.1%. As of June 30, 2026, Santander Chile employs 8,315 people and has 224 branches throughout Chile.

Company to feature surgeon-led educational programming and technologies supporting liver surgery

PRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences (Nasdaq: IART) will mark 20 years of CUSA® technology within its portfolio at the American College of Surgeons (ACS) Clinical Congress 2026, taking place September 26-29 in Washington, D.C. The company will feature surgeon-led educational programming focused on liver surgery, including presentations and clinical discussions featuring the CUSA Clarity Ultrasonic Surgical Aspirator System and MicroFrance® laparoscopic surgical instrumentation.

As part of ACS’s Innovation Theater programming, Integra LifeSciences will feature presentations from internationally recognized liver surgeons to share clinical perspectives and experience with approaches to complex liver procedures. With more than 800,000 people diagnosed with liver cancer worldwide each year¹, continued education and collaboration in liver surgery remain important for the treatment of patients with complex hepatobiliary conditions, including liver tumors.

Presenters include:

• Goro Honda, M.D., Ph.D., FACS, Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University
• Adnan Alseidi, M.D., M.Ed., M.B.A., FACS, professor of surgery, University of California, San Francisco (UCSF) and specialist in liver, pancreas and biliary surgery

“The ACS Congress provides an important opportunity to engage with the surgical community and exchange perspectives,” said Harvinder Singh, executive vice president and president, Specialty Surgery, Integra LifeSciences. “As we mark 20 years of CUSA within the Integra LifeSciences portfolio, we are proud of the role this technology plays in supporting surgeons globally. Integra LifeSciences remains focused on building upon proven technologies while addressing evolving clinical needs.”

Conference attendees are invited to visit Integra LifeSciences at Booth 428 and participate in the company’s Innovation Theater programming.

About CUSA® Clarity Ultrasonic Surgical Aspirator System

The CUSA Clarity Ultrasonic Surgical Aspirator System is indicated for use in surgical procedures where fragmentation, emulsification and aspiration of soft and hard (e.g. bone) tissue is desirable, such as neurosurgery, plastic and reconstructive surgery, orthopedic surgery, thoracic surgery, laparoscopic surgery, gynecological surgery, cardiac surgery and liver resection and transplant surgery.

About MicroFrance® Laparoscopic Instruments

The MicroFrance® laparoscopic manual surgical instruments are intended for use in a wide variety of surgical procedures, including laparoscopic and endoscopic procedures. The instruments are intended to scrape, cut, grasp, hold, remove, or manipulate tissue or structures.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections and involve inherent risks, assumptions and uncertainties that are difficult to predict and which may be beyond our control. These forward-looking statements include, but are not limited to, statements related to the potential applications and efficacy of the Integra LifeSciences products described herein and the realization of improvements to health outcomes. There can be no assurance that previously observed benefits will be replicated. The actual effect of the use of these products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will achieve or maintain commercial success. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra LifeSciences’ business, particularly those identified under the headings “Risk Factors” and “Special Note Regarding Forward-Looking Statements,” included in Integra LifeSciences’ Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. The forward-looking statements included in this news release are made only as of the date of this news release and Integra LifeSciences undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

_______________________
¹ American Cancer Society. Key Statistics About Liver Cancer. Updated Jan. 13, 2026. Accessed Sept. 23, 2026. American Cancer Society liver cancer statistics. [cancer.org]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/17d68748-4f8c-49e3-9da4-8f181ede652b

DENVER, Sept. 25, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — A completed library of living genetic building blocks positions Kraig Biocraft Laboratories (OTCQB: KBLB) to explore more than 200 potential configurations and pursue its ultimate goal of combining the full Atlas suite in one production strain.

Darwin’s bark spider offers a remarkable demonstration of what nature can engineer. Its silk ranks among the toughest natural fibers ever measured, with landmark research reporting roughly ten times the toughness of Kevlar a measure of how much energy a material can absorb before breaking. That extraordinary performance helps explain the enormous interest in turning spider silk biology into commercially useful materials.

It also provides context for a major development at Kraig Biocraft Laboratories.

According to the company’s release, Kraig has successfully integrated every planned Project Atlas transgene into living commercial silkworm hosts, completing its foundational Atlas Gene Library.

For readers following the company, the significance goes beyond the completion of a research collection. Kraig now has the full planned set of genetic building blocks inside living silkworms, establishing the foundation to combine those technologies and test what they can accomplish together.

The company says the library enables more than 200 potential genetic configurations. Its ultimate objective is to combine the full suite of Atlas genetics into a single production strain with advanced material properties.

Successfully completing that integration and demonstrating the intended performance could mark a historic milestone for Kraig and a significant advance in engineered biomaterials.

“Completing the Atlas Gene Library is a defining milestone for Project Atlas,” said Dr. Xiaoli Zhang, Kraig’s Chief Scientist. “Every planned Atlas transgene has now been established in commercial silkworm hosts, giving us the complete set of genetic building blocks we envisioned when Project Atlas began.”

The scale of the opportunity becomes clearer when considering how materials are used. An industrial fiber may need to withstand repeated stress. A protective textile may require energy absorption and flexibility. Different applications demand different combinations of properties.

Atlas is designed to pursue enhanced strength, toughness, and flexibility beyond Kraig’s current recombinant spider silk production line. Its genetic library could give researchers a way to explore multiple fiber designs and identify combinations suited to different performance requirements.

The Darwin’s bark spider comparison makes that ambition tangible. Nature has already demonstrated extraordinary silk performance. The engineering challenge is to translate that potential into useful fibers within a practical production system. Testing will establish the performance of Atlas-derived materials.

Kraig’s earlier work provides an important foundation for understanding the direction of the program. The company previously reported knock-in/knock-out gene-editing technology for producing nearly pure spider silk, demonstrating its ability to make targeted changes to silkworm silk genetics. That history provides context for Atlas’s broader ambition of bringing multiple advanced genetic technologies together in one strain.

The next stage is to establish stable homozygous breeding lines carrying matching copies of the relevant genetic insert. Those lines will provide the foundation for systematically assembling combinations and evaluating the resulting fibers.

For investors, this creates a concrete sequence of milestones to follow: stable breeding lines, successful genetic combinations, measured material performance, and selection of candidates for further commercial development.

The more than 200 configurations represent potential designs to investigate. Their value will emerge as researchers determine which combinations produce useful properties and can support reliable production.

Kraig says Atlas is advancing alongside its commercial spider silk production operations. That parallel development is central to the opportunity: better-performing materials need a manufacturing system capable of delivering them consistently.

With the Atlas Gene Library complete, Kraig has assembled the building blocks for its next major scientific push. The coming phases will test whether those components can work together to deliver a new generation of advanced fibers and how far the company can extend the commercial possibilities of engineered spider silk.

• Agnarsson, Kuntner & Blackledge (2010)—PLOS ONE
  The original study reported average silk toughness of approximately 350 MJ/m³, with some samples reaching 520 MJ/m³, and a comparison of more than ten times the toughness of Kevlar. This is the main source to link in the PR.
• Garb and colleagues (2019)—Communications Biology
  Examines the silk proteins that may contribute to this exceptional toughness and reiterates the tenfold Kevlar comparison, explaining the combination of strength and unusual stretchability.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

IRVINE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced its participation in several upcoming investor conferences in October 2026. SBC Medical will conduct presentations and one-on-one meetings with institutional investors.

Below is a summary of the Company’s scheduled participation in upcoming investor conferences:

Noble Capital Markets October 2026 Emerging Growth Virtual Equity Conference
Date: October 1-2, 2026
Format: Virtual
Registration: Link

Maxim Growth Summit 2026
Date: October 14, 2026
Format: In-person (New York)
Registration: Link

The ThinkEquity Conference 2026
Date: October 15, 2026
Format: In-person (New York)
Registration: Link

About SBC Medical Group Holdings Incorporated

SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, Hair Loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000^® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com

For more insights and updates from SBC Medical, follow us on LinkedIn

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Contacts

Hikaru Fukui
Head of IR Department
E-mail: ir@sbc-holdings.com

Kodiak on target to complete its safety case validation and begin unsupervised driverless highway service by year end

Under Kodiak’s driverless launch program, the company is conducting daily preparation runs along Interstate 45, as well as driverless validation testing at closed-course test tracks

MOUNTAIN VIEW, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) — Kodiak AI, Inc. (“Kodiak”) (Nasdaq: KDK), a leading provider of Physical AI-powered autonomous driving technology, today announced its plans to launch unsupervised long-haul driverless service on the Dallas-Houston freight lane by the end of 2026.

Kodiak began its driverless long-haul launch program in August on its driverless-ready software and hardware platform, and now consistently completes deliveries between its Lancaster, Texas, hub and its launch destination in Houston without human intervention. During these end-to-end deliveries, the safety observer never touched the wheel, including on surface streets.

A video of a complete, end-to-end delivery is available here.

The company’s driverless launch program is designed to complete the final testing and validation necessary for Kodiak’s initial long-haul safety case. Kodiak has operated daily test drives since August on its launch platform and conducted driverless testing at closed-course test tracks. These drives are part of Kodiak’s final validation process before commencing driver-out operations.

Kodiak’s growing record of intervention-free deliveries on its launch lane demonstrates its driverless readiness.

“Our progress since beginning our final push towards driverless commercial deliveries has been incredible, and it is a strong signal we are ready to scale unsupervised driverless service on long-haul lanes,” said Don Burnette, Founder and Chief Executive Officer of Kodiak. “We have almost two years experience in driverless operations – no human in the cab – for a paying customer in the Permian Basin. Our final driverless launch initiative has readied the same Kodiak Driver for highways, and the results are exactly what we anticipated. We are on track to complete our preparations and launch driverless highway service by the end of this year.”

As of the end of August, Kodiak’s Autonomy Readiness Measure (ARM) for the long-haul domain stood at 93%. The ARM measures the percentage of claims and evidence in Kodiak’s safety case for driverless operations that are materially complete. Kodiak’s safety case is a structured argument, supported by evidence, that the Kodiak Driver, the company’s autonomous driving system, can operate safely in a defined operating environment. The company expects to reach 100% and launch driverless operations by year end.

Dallas to Houston: Kodiak’s first driverless lane

Kodiak’s first driverless long-haul lane will connect the Dallas–Fort Worth and Houston metropolitan areas, 219 miles apart along Interstate 45. The DFW to Houston route represents one of the densest freight lanes in the United States. Kodiak has delivered freight on the Dallas to Houston route since 2019 with safety drivers in the cab. Over that time, the company has driven more than 3.5 million autonomous miles.

Preparing for launch at the test track

Concurrently, Kodiak is conducting driverless tests at closed-course test tracks, where it is deliberately stress-testing the Kodiak Driver under real-world conditions that occur too rarely, or are too risky, to test on public highways. Together, the programs give Kodiak the testing and validation required to close its safety case in advance of driverless highway launch.

Permian provides a proven driverless foundation

Kodiak’s long-haul driverless launch builds on the company’s nearly two years of commercial driverless operations in the industrial sector. In December 2024, Kodiak became the first company to deploy driverless technology in customer owned-and-operated trucks, when the company began hauling freight with no one in the cab with Atlas Energy Solutions in the Permian Basin of West Texas and Eastern New Mexico.

As of June 30, 2026, the Kodiak Driver had been integrated into 35 driverless trucks owned and operated by Atlas and surpassed 40,000 cumulative hours of paid driverless operations.

Forward Looking Statements

This press release includes forward-looking statements including regarding Kodiak’s or its management teams’ expectations, hopes, beliefs, intentions or strategies regarding the future. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “forecast,” “intend,” “expect,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding: expectations regarding the benefits and performance of Kodiak’s technology; Kodiak’s expectations with respect to closing its long-haul safety case and launching driverless operations on public highways in Texas by the end of 2026; and Kodiak’s expectations with respect to its future performance and success. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Kodiak’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied upon by any investors as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Kodiak. These forward-looking statements are subject to a number of risks and uncertainties, including changes in business, market, financial, political and legal conditions; the rapid evolution of autonomous vehicle technology and flaws or errors in Kodiak’s solutions or flaws in or misuse of autonomous vehicle technology in general; risks related to the rollout of Kodiak’s business and the timing of expected business milestones; the effects of competition on Kodiak’s business; supply shortages in the materials necessary for the production of the Kodiak Driver; risks related to working with third-party manufacturers for key components of the Kodiak Driver; risks related to the retrofitting of Kodiak’s vehicles by third parties; the termination or suspension of any of Kodiak’s contracts or the reduction in counterparty spending; delays in Kodiak’s operational roadmap with key partners and customers; and Kodiak’s ability to raise capital in the near term and long term. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by Kodiak with the Securities and Exchange Commission, including under the heading “Risk Factors.” If any of these risks materialize or any assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Kodiak does not presently know, or that Kodiak currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

In addition, forward-looking statements reflect Kodiak’s expectations, plans or forecasts of future events and views as of the date they are made. Kodiak anticipates that subsequent events and developments will cause Kodiak’s assessments to change. However, while Kodiak may elect to update these forward-looking statements at some point in the future, Kodiak specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Kodiak’s assessments as of any date subsequent to the date they are made.

About Kodiak AI, Inc.
Kodiak AI, Inc. (Nasdaq: KDK) is a leader in Physical AI, developing driverless technology that powers machines that move. The core of the company’s solution is the Kodiak Driver, a vehicle-agnostic autonomous driving system that combines advanced AI-powered software with modular hardware. Today, the Kodiak Driver operates in the long-haul trucking, industrial trucking, and defense sectors, and is already deployed in commercial operation with no one in the cab. Kodiak AI commercializes its technology through both a Driver-as-a-Service business model and strategic partnerships. In 2024, Kodiak achieved a historic milestone, becoming the first company to deploy driverless technology in customer-owned driverless semi-trucks. Commercial partners and customers include Atlas Energy Solutions, IKEA, Bridgestone, Werner Enterprises, C.R. England, General Dynamics Land Systems, and Roehl Transport.

For more information about Kodiak, please visit https://kodiak.ai/investors. Kodiak’s press kit with videos and images can be found HERE.

Kodiak Media Contacts
Pete Bigelow
Public Relations Manager, Kodiak AI
+1 303-443-4441
pete.bigelow@kodiak.ai

Kylee Keskerian
PR Consultant for Kodiak AI
+1 419-822-6417
kylee@futuristacommunications.com

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/5f1d23d9-a29f-4aed-9214-a950caaf8660

NEW YORK and LONDON and LEAMINGTON, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, hospitality and wellness industries, today announced that the Company will release its financial results for the first fiscal quarter ended August 31, 2026, before the financial markets open on Thursday, October 8, 2026.

Live Conference Call and Audio Webcast

Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Tilray’s Investor Relations website.

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Contacts:

Tilray Brands Media: news@tilray.com

Investors: investors@tilray.com

SARASOTA, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 11:30 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/Yy1V3pgKbZQ. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/. 

About INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on U.S.-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. For more information, please visit invofertility.com.

For more information, please contact:

INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com

Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com

GREENWOOD VILLAGE, Colo., Sept. 25, 2026 (GLOBE NEWSWIRE) — Umbra Companies Inc. (“Umbra” or the “Company”) (OTC: UCIX) today announced its intention to transition to fully reporting status and to file a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”). The Company currently expects to file the S-1 in early October 2026.

Benefits to Shareholders of Going Fully Reporting

Umbra believes becoming fully reporting with the SEC can create meaningful, long-term value for shareholders by strengthening transparency, improving disclosure consistency, and enhancing overall investor confidence. Key shareholder benefits include:

Greater Transparency and Visibility

• Investors gain access to SEC-standard disclosures that are more consistent and easier to track over time.

Improved Disclosure Quality and Consistency

• SEC reporting provides a structured cadence and established reporting expectations, supporting clearer and more reliable communication.

Enhanced Credibility with Investors and Market Participants

• SEC filings serve as a recognized benchmark for public-company disclosure and can reinforce confidence in the Company’s commitment to accountability.

Better Comparability for Shareholders

• SEC reporting helps investors evaluate Umbra using familiar reporting formats and timelines.

Potential to Broaden Investor Access

• Many investors and platforms prioritize SEC-reporting companies, which may improve liquidity and access over time.

Building on a Strong Record of Quarterly Financial Updates

Umbra notes that it has been providing quarterly financial information to investors for the past five years. The Company’s move toward SEC fully reporting is intended to build on that track record by transitioning from periodic updates to an ongoing SEC reporting framework with standardized disclosure.

“Our priority has always been delivering clear financial visibility to shareholders,” said Rohn Monroe, CEO of Umbra Companies Inc. “Moving toward full SEC reporting and filing an S-1 in early October 2026 is designed to strengthen transparency, improve consistency, and support long-term shareholder value.”

About Umbra Companies Inc.

Umbra Companies Inc. is a public company traded on the OTC Markets under the ticker symbol UCIX. Investor information is available at umbracompaniesinc.com.

Forward-Looking Statements

This press release includes forward-looking statements, including statements regarding the Company’s intention to become fully reporting and to file an S-1 with the SEC, and the Company’s expected timing. These statements involve risks and uncertainties, including the SEC’s review process and whether any such registration statement is declared effective. The Company undertakes no obligation to update these forward-looking statements except as required by law.

CONTACT: Contact
Umbra Companies Inc.
6312 S. Fiddlers Circle Suite 300E 
Greenwood Village, CO 80111
O: +1.833.833.2913
Pr@umbraucix.com  
Website: umbracompaniesinc.com